Results 271 to 280 of about 4,589,938 (338)
Some of the next articles are maybe not open access.

Guidelines for Thrombolytic Therapy for Frostbite.

Journal of Burn Care & Research, 2020
The data are insufficient to support standardized treatment of all patients with frostbite with thrombolytic therapy. The following guidelines, however, should be applied to all patients with cyanosis persisting proximal to the distal phalanx (Grade 3 or
Sean A. Hickey   +13 more
semanticscholar   +1 more source

Thrombolytic Therapy

Annual Review of Medicine, 1988
Despite their widespread use in patients with acute myocardial infarction, all currently available thrombolytic agents suffer from a number of significant limitations, including resistance to reperfusion, the occurrence of acute coronary reocclusion and bleeding complications.
D, Collen, D C, Stump, H K, Gold
  +7 more sources

Thrombolytic therapy

Annals of Emergency Medicine, 1993
All patients with symptoms and ECG findings suggestive of acute myocardial infarction (AMI) should be considered for treatment with thrombolytic agents. The decision to use thrombolytic therapy is a clinical judgment based upon a weighing of the potential benefits versus the possible risks.
Eisenberg, M.   +5 more
openaire   +3 more sources

Thrombolytic Therapy for Acute Ischemic Stroke: Past and Future.

Current pharmaceutical design, 2019
BACKGROUND Thromboembolic ischemic stroke, which is mainly caused by hypertension, as well as plasma dyslipidemia, arterial fibrillation and diabetes, is a leading cause of death in the US and other countries.
K. Shibata   +4 more
semanticscholar   +1 more source

Thrombolytic Therapy

Emergency Medicine Clinics of North America, 1995
If the electrocardiogram is diagnostic of acute myocardial infarction (AMI) in the patient complaining of typical chest pain, then indications and contraindications for thrombolytic therapy must be assessed immediately. The goal is to administer a thrombolytic agent within 30 to 60 minutes of presentation to the emergency department.
G P, Young, J R, Hoffman
openaire   +2 more sources

Thrombolytic therapy

Blood Reviews, 1989
The accepted role for thrombolytic therapy has until recently been limited because of its complexity and side-effects. It has generally been reserved for use systemically in a limited number of patients with acute, major pulmonary embolism or iliofemoral venous thrombosis, and locally in some patients with acute, peripheral arterial occlusion.
openaire   +2 more sources

Thrombolytic therapy in pregnancy

Journal of Thrombosis and Thrombolysis, 2006
Pregnancy due to its physiological changes is a procoagulant state. The rate of cardiac valve prosthesis thrombosis, deep venous thrombosis and pulmonary embolism are all increased. Thrombolytic therapy with tissue plasminogen activator (rt-PA) is an approved therapy for ischemic stroke, myocardial infarction, pulmonary embolism and thrombosis of ...
Georg, Leonhardt   +4 more
openaire   +2 more sources

Thrombolytic therapy for stroke

Current Opinion in Neurology, 1994
The physiology of thrombi and the pharmacology of thrombolytic drugs are under active study and improved regimens for the dosing of thrombolytic agents have been developed. In the setting of myocardial infarction, recently reported differences among thrombolytic agents have been slight, including the frequency of thrombolysis-associated hemorrhagic ...
T, Brott, J, Broderick, R, Kothari
openaire   +2 more sources

Monitoring thrombolytic therapy

Progress in Cardiovascular Diseases, 1992
HROMBOLYTIC THERAPY for acute myocardial infarction (MI) now represents the standard of care for many patients. A large number of clinical trials have demonstrated improvement in survival and cardiac function following treatment of acute MI with thrombolytic agents,‘.’ and the use of thrombolytic therapy is rapidly spreading to community hospitals.
E G, Bovill, R, Becker, R P, Tracy
openaire   +2 more sources

Thrombolytic therapy in the elderly

The Lancet, 2000
Elderly patients have the highest absolute risk of death following an acute myocardial infarction (MI); 16.1% for those aged between 65 and 74 years, and 25.3% for those older than 75 years. Therefore, this age-group potentially may benefit most from the use of thrombolytic therapy.
openaire   +2 more sources

Home - About - Disclaimer - Privacy